Imerys says divestiture of its paper market assets to Syntagma Capital is unlikely; company to consider alternative options for divestment

Sample article from our Chemicals Industry

October 2, 2023 (press release) –


Imerys today announces that the completion of the proposed divestiture of its assets serving the paper market has become highly unlikely to materialize due to circumstances for which Imerys has formally reserved its rights towards Syntagma Capital.

At the end of 2022, Imerys signed a binding agreement with Syntagma Capital for the sale of most of its assets serving the paper market. These activities represented less than 10% of Imerys’ revenue in 2022.

Imerys’ focus on its core business of high-growth specialty minerals remains unchanged and the Group will explore alternative options for the divestment of this business. In the meantime, Imerys will continue to manage these assets in the best interest of the Group, its employees, and its customers.

The Group's guidance for full-year 2023 current EBITDA was set at current perimeter on July 27th and is therefore not to be affected by today’s announcement.

The world’s leading supplier of mineral-based specialty solutions for industry with €4.3 billion in revenue and 14,000 employees in 2022. Imerys delivers high value-added, functional solutions to a great number of sectors, from processing industries to consumer goods. The Group draws on its understanding of applications, technological knowledge and expertise in material science to deliver solutions by beneficiating its mineral resources, synthetic minerals and formulations. Imerys’ solutions contribute essential properties to customers’ products and their performance, including heat resistance, hardness, conductivity, opacity, durability, purity, lightness, filtration, absorption and water repellency. Imerys is determined to develop responsibly, in particular by fostering the emergence of environmentally-friendly products and processes.

More comprehensive information about Imerys may be obtained from its website ( in the Regulated Information section, particularly in its Registration Document filed with the French financial markets authority (Autorité des marchés financiers, AMF) on March 22, 2022 under number D.22-0131 (also available from the AMF website, Imerys draws investors’ attention to chapter 2 “Risk Factors and Internal Control” of its Registration Document.

Disclaimer: This document contains projections and other forward-looking statements. Investors should be aware that such projections and forward-looking statements are subject to various risks and uncertainties (many of which are difficult to predict and generally beyond the control of Imerys) that could cause actual results and developments to differ materially from those expressed or implied.


Press contacts:

Claire Garnier : +33 (0)6 25 50 94 92

Hugues Schmitt (Primatice) : + 33(0) 6 71 99 74 58 

Analyst/Investor Relations: 

Cyrille Arhanchiague : +33 (0)1 49 55 64 84



* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

More from our Chemicals Industry Coverage
See our dashboard in action - schedule an demo
Dan Rivard
Dan Rivard
- VP Market Development -

We offer built-to-order chemicals industry coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.